Home
HelpTest Code CMVAB Cytomegalovirus Antibody, IgM and IgG, Serum
Specimen Required
Supplies: Sarstedt Aliquot Tube 5 mL (T914)
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.7 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial
Useful For
Aiding in determining the serological status to cytomegalovirus
Profile Information
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| CMVMS | CMV Ab, IgM, S | Yes | Yes |
| CMVGS | CMV Ab, IgG, S | Yes | Yes |
Method Name
Electrochemiluminescence Immunoassay (ECLIA)
Reporting Name
CMV Ab, IgM and IgG, SSpecimen Type
SerumSpecimen Minimum Volume
0.7 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Serum | Refrigerated (preferred) | 28 days |
| Frozen | 90 days | |
| Ambient | 7 days |
Reference Values
CYTOMEGALOVIRUS IgM
Negative
CYTOMEGALOVIRUS IgG
Negative
Reference values apply to all ages.
Interpretation
Negative:
Negative for cytomegalovirus (CMV) IgM and IgG. False negative results may occur in immunocompromised patients.
Borderline:
Recommend follow-up testing in 10 to14 days if clinically indicated.
Positive IgG:
CMV IgG antibodies detected, which indicate recent or remote infection. These individuals may transmit CMV to susceptible individuals through blood and tissue products.
Positive IgM:
CMV IgM antibodies detected, which may indicate active or recent infection. Low level IgM antibodies may persist for more than 12 months following disease resolution.
Clinical Reference
1.Fowler K, Mucha J, Neumann M, et al. A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development. BMC Public Health. 2022;22(1):1659. Published 2022 Sep 1. doi:10.1186/s12889-022-13971-7
2.Limaye AP, Babu TM, Boeckh M. Progress and challenges in the prevention, diagnosis, and management of cytomegalovirus infection in transplantation. Clin Microbiol Rev. 2020;34(1):e00043-19Published 2020 Oct 28. doi:10.1128/CMR.00043-19
3.Leber AL. Maternal and congenital human cytomegalovirus infection: laboratory testing for detection and diagnosis [published correction appears in J Clin Microbiol. 2024 Sep 11;62(9):e0116424. doi: 10.1128/jcm.01164-24.]. J Clin Microbiol. 2024;62(4):e0031323. doi:10.1128/jcm.00313-23
4.Bruminhent J, Thongprayoon C, Dierkhising RA, Kremers WK, Theel ES, Razonable RR. Risk factors for cytomegalovirus reactivation after liver transplantation: can pre-transplant cytomegalovirus antibody titers predict outcome?. Liver Transpl. 2015;21(4):539-546. doi:10.1002/lt.2407
5.Dioverti MV, Razonable RR. Cytomegalovirus. In: Hayden RT, Wolk DM, Carroll KC, Tang YW, eds. Diagnostic Microbiology of the Immunocompromised Host; 2016:97-125
Day(s) Performed
Monday through Saturday
Report Available
Same day/1 to 3 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
86645-Cytomegalovirus IgM
86644-Cytomegalovirus IgG
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| CMVAB | CMV Ab, IgM and IgG, S | 87424-8 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| MCMV | CMV Ab, IgM, S | 30325-5 |
| GCMV | CMV Ab, IgG, S | 22244-8 |